{"id":2823,"date":"2010-08-29T02:00:09","date_gmt":"2010-08-29T06:00:09","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=2823"},"modified":"2011-07-19T17:44:52","modified_gmt":"2011-07-19T21:44:52","slug":"alpha-omega-trial-tests-n-3-fatty-acids-in-cv-disease","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/08\/29\/alpha-omega-trial-tests-n-3-fatty-acids-in-cv-disease\/","title":{"rendered":"Alpha Omega Trial Tests Omega-3 Fatty Acids in CV Disease"},"content":{"rendered":"<p>To test the effect of omega-3 fatty acids in cardiovascular disease, Kromhaut and colleagues with the Alpha Omega Trial Group randomized 4837 patients with a history of MI to treatment with one of four margarine preparations: one containing EPA and DHA; one with ALA; one with EPA, DHA, and ALA; or placebo. After 40 months, the rate of major cardiovascular events did not differ significantly across any of the groups. Among women, there was a trend toward a reduction in events in those who received ALA compared with those who received placebo or EPA\/DHA. The results were presented at the ESC in Stockholm and <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1003603\">published simultaneously in the <em>New England Journal of Medicine<\/em><\/a>.<\/p>\n<p>&#8220;The patients in this trial were very well treated,&#8221; said Dr. Kromhout, in an ESC press release, &#8220;with 98% on antithrombotic agents, 90% on antihypertensive drugs, and 86% on lipid lowering drugs. We found that cardiovascular mortality rate in the study population was only half that expected, probably because of their excellent treatment. This may also be why the rate of major cardiovascular events during follow-up was no lower in the fatty acid groups than in the placebo group. &#8220;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>To test the effect of omega-3 fatty acids in cardiovascular disease, Kromhaut and colleagues with the Alpha Omega Trial Group randomized 4837 patients with a history of MI to treatment with one of four margarine preparations: one containing EPA and DHA; one with ALA; one with EPA, DHA, and ALA; or placebo. After 40 months, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[333],"class_list":["post-2823","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-n-3-fatty-acids"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/2823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=2823"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/2823\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=2823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=2823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=2823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}